<DOC>
	<DOCNO>NCT03010735</DOCNO>
	<brief_summary>The purpose study investigate effect oral administration Bifidobacterium animalis A6 metabolism uremic toxin , patient End Stage Renal Disease ( ESRD ) . One hundred fifty hemodialysis patient recruit , Double Blind Randomized Parallel Controlled Trial performed.The microbiota-derived uremic toxin , indoxyl sulfate p-cresol sulfate , measure Primary Outcome . The Fecal microbiome , fecal metabolite , blood metabolite , defecation , Gastrointestinal Symptoms The Kidney Disease Quality Life The Occurrence Cardiovascular Event also assess .</brief_summary>
	<brief_title>Effects Probiotics Patients With End Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Age 18 year old Patients diagnose ESRD hemodialysis Fixed hemodialysis cycle ( average 3 time week ) Agree take product study study period , long take ferment dairy product ( live lactic acid bacteria drink , cheese , yogurt , probiotic product , etc . ) Agree sign inform consent form Taking antibiotic antifungal drug within 30 day study Have serious allergic reaction skim milk powder Researcher sure whether subject willing able complete study Subject participate research project within two month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Probiotics</keyword>
	<keyword>Uremic toxin</keyword>
	<keyword>Gastrointestinal Microbiome</keyword>
</DOC>